1. Articles in category: News

    1-24 of 159 1 2 3 4 5 6 7 »
    1. Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      Biochem Biophys Res Commun. 2017 Jul 12;:

      Authors: Li Y, Zhuo B, Yin Y, Han T, Li S, Li Z, Wang J

      Abstract Chemotherapy is one of the few effective choices for patients with neuroblastoma. However, the development of muti-drug resistance (MDR) to chemotherapy is a major obstacle to the effective treatment of advanced or recurrent neuroblastoma.

      Read Full Article
    2. New potential treatment for aggressive types of childhood cancer

      New potential treatment for aggressive types of childhood cancer

      A combination of substances that impacts chemical modifications in the DNA of tumours and triggers the tumours to differentiate into harmless nerve cells could represent a new method of treating aggressive forms of neuroblastoma. The new method has been proposed by researchers at Karolinska Institutet, after studies using mice showed that the combination treatment resulted in a significant suppression in tumour growth.

      Read Full Article
      Mentions: Treatment
    3. γδTFH cells promote B cell maturation and antibody production in neuroblastoma.

      γδTFH cells promote B cell maturation and antibody production in neuroblastoma.

      BMC Immunol. 2017 Jul 07;18(1):36

      Authors: Mou W, Han W, Ma X, Wang X, Qin H, Zhao W, Ren X, Chen X, Yang W, Cheng H, Wang X, Zhang H, Ni X, Wang H, Gui J

      Abstract BACKGROUND: Previous studies have shown that γδ TFH cells are capable of modulating antibody production in immunized and infected mouse model.

      Read Full Article
      Mentions: Antibody
    4. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.

      Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.

      Tumour Biol. 2017 Jul;39(7):1010428317701309

      Authors: Krishnadas DK, Wang Y, Sundaram K, Bai F, Lucas KG

      Abstract The cancer germline antigens MAGE-A1, MAGE-A3, and NY-ESO-1 can be used to target relapsed or therapy-resistant malignant solid tumors, and previous studies have demonstrated that these antigens can be epigenetically upregulated on the surface of tumor cells following exposure to low-dose demethylating chemotherapy agents, such as decitabine. The extent to which cancer germline antigen cytotoxic T lymphocytes can be reliably expanded from healthy donors has not been well characterized, specifically in ...

      Read Full Article
    5. Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.

      Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.

      Pediatr Blood Cancer. 2017 May;64(5):

      Authors: Jiménez I, Baruchel A, Doz F, Schulte J

      Abstract The last few years have seen the identification of pharmacologic approaches to target bromodomain and extraterminal (BET) proteins for cancer treatment.

      Read Full Article
      Mentions: Treatment
    6. Neonates with cancer and causes of death; lessons from 615 cases in the SEER databases.

      Neonates with cancer and causes of death; lessons from 615 cases in the SEER databases.

      Cancer Med. 2017 Jun 22;:

      Authors: Alfaar AS, Hassan WM, Bakry MS, Qaddoumi I

      Abstract Neonatal tumors are rare with no standard treatment approaches to these diseases, and the patients experience poor outcomes. Our aim was to determine the distribution of cancers affecting neonates and compare survival between these cancers and older children.

      Read Full Article
      Mentions: Treatment
    7. New biomarker assay detects neuroblastoma with greater sensitivity

      Investigators have developed and tested a new biomarker assay for quantifying disease and detecting the presence of neuroblastoma even when standard evaluations yield negative results for the disease. Researchers provide the first systematic comparison of standard imaging evaluations versus the new assay that screens for five different neuroblastoma-associated genes and determine that the new assay improves disease assessment and provides prediction of disease progression.

      Read Full Article
      Mentions: NANT Imaging MIBG
    8. New biomarker assay detects neuroblastoma with greater sensitivity

      New biomarker assay detects neuroblastoma with greater sensitivity

      ( Children's Hospital Los Angeles ) Investigators at The Saban Research Institute of Children's Hospital Los Angeles have developed and tested a new biomarker assay for quantifying disease and detecting the presence of neuroblastoma even when standard evaluations yield negative results for the disease.

      Read Full Article
      Mentions: NANT MIBG
    9. New research points to potential targeted treatments of neuroblastoma tumours

      New research points to potential targeted treatments of neuroblastoma tumours

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine.

      The findings lay the groundwork for developing more targeted treatments for...

      Read Full Article
      Mentions: MYCN
    10. Potential for more targeted treatments of neuroblastoma tumors

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    11. New research points to potential for more targeted treatments of neuroblastoma tumors

      New research points to potential for more targeted treatments of neuroblastoma tumors

      ( University of Chicago Medical Center ) Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    12. CFC1 is a cancer stemness-regulating factor in neuroblastoma.

      CFC1 is a cancer stemness-regulating factor in neuroblastoma.

      Oncotarget. 2017 Jun 13;:

      Authors: Chikaraishi K, Takenobu H, Sugino RP, Mukae K, Akter J, Haruta M, Kurosumi M, Endo TA, Koseki H, Shimojo N, Ohira M, Kamijo T

      Abstract BACKGROUND: Despite the use of aggressive therapy, survival rates among high-risk neuroblastoma (NB) patients remain poor. Cancer stem cells (CSCs) are considered to be critically involved in the recurrence and metastasis of NB and are isolated as NB spheres.

      Read Full Article
      Mentions: Metastasis
    13. NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells.

      NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells.

      J Immunother. 2017 Jun 15;:

      Authors: Shoae-Hassani A, Hamidieh AA, Behfar M, Mohseni R, Mortazavi-Tabatabaei SA, Asgharzadeh S

      Read Full Article
      Mentions: NK Cells
    14. Giving children a voice in clinical trials

      Giving children a voice in clinical trials

      ( Children's National Health System ) Children as young as 8 years old with incurable cancer can reliably characterize the impact an experimental therapy has on their symptoms and quality of life -- even at the earliest stages of drug development -- making self-reported patient outcomes a potential new clinical trial endpoint.

      Read Full Article
    15. NCI-MATCH cancer trial reaches 6,000-patient tumor sequencing goal 2 years early

      NCI-MATCH cancer trial reaches 6,000-patient tumor sequencing goal 2 years early

      "The rapid pace of patient enrollment in the National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine cancer treatment trial will result in the study reaching its goal of sequencing the tumors of 6,000 patients in June, nearly two years sooner than expected. The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), which is leading this signal-finding trial under the sponsorship of the National Cancer Institute (NCI), reports that wide-scale adoption throughout the NCI National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP) caused the unprecedented rate of patient enrollment."

      Read Full Article
    16. YmAbs Announces Positive Topline Result in Pivotal Study of burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma

      YmAbs Announces Positive Topline Result in Pivotal Study of burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma

      "Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced positive top line results from a pivotal study of 131I-burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma. Results showed a 58 months average survival for the patients treated with 131I-burtomab in the study, compared to an average of 4.7 month and no long term survival or cure, for a contemporary cohort in the Central German Childhood Cancer Registry. After more than a decade of follow-up, data shows more than 40% overall long term survival indicating that the treated children have ...

      Read Full Article
    17. Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

      Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

      Larotrectinib (LOXO-101) has demonstrated consistent and durable antitumor activity in tropomyosin receptor kinase (TRK) fusion cancers across a wide range of patient ages and tumor types and was well tolerated by patients, according to results from three clinical trials presented today at the annual meeting of the American Society of Clinical Oncology in Chicago.

      Read Full Article
    18. Chronic health conditions among long-term survivors of childhood cancer decrease over three decades as treatments improve

      Chronic health conditions among long-term survivors of childhood cancer decrease over three decades as treatments improve

      MEMPHIS, Tenn., June 2, 2017 /PRNewswire/ -- Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CC...

      Read Full Article
      Mentions: Treatment
    19. Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma.

      Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma.

      BMC Cancer. 2017 May 19;17(1):352

      Authors: Bettinsoli P, Ferrari-Toninelli G, Bonini SA, Prandelli C, Memo M

      Abstract BACKGROUND: Neuroblastoma is the most common extracranial solid malignancy in childhood, responsible for 15% of all pediatric cancer deaths.

      Read Full Article
      Mentions: MYCN
    20. A new molecular target to improve neuroblastoma treatment

      The collaborative work, in which UPV/EHU and Achucarro Center researchers have participated, has served to identify some genetic mutations that will help to improve the treatment of this disease The annual mortality rate in childhood cancer of the sympathetic nervous system, or neuroblastoma, is 10 per million between the ages of 0 and 4. The […]

      The post A new molecular target to improve neuroblastoma treatment appeared first on Healthcanal.com.

      Read Full Article
      Mentions: Treatment
    1-24 of 159 1 2 3 4 5 6 7 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Organizations in the News

    1. (3 articles) NANT
  4. Researches in the News

    1. (1 articles) Antibody
    2. (1 articles) Immunotherapy
    3. (1 articles) MYCN
    4. (1 articles) Imaging
  5. General Informations in the News

    1. (4 articles) Treatment
  6. Treatments in the News

    1. (3 articles) MIBG
    2. (2 articles) Chemotherapy